Shuntaro Sato

Nagasaki University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Background Although utility of composite trait‐specific polygenic risk score (multi‐trait PRS) has been examined among European ancestries, few studies investigated among East Asians and incorporated modifiable risk factors. We examined the associations of multi‐trait PRS for cardiometabolic factors with cardiovascular disease mortality by integrating nongenetic determinants. Methods A total of 14 086 Japanese participants (mean age, 55±9; 55.8% women) of the J‐MICC (Japan Multi‐Institutional Collaborative Cohort) study were analyzed in this study. We calculated 6 PRSs for cardiometabolic traits (systolic blood pressure, body mass index, triglycerides, low‐density lipoprotein cholesterol, estimated glomerular filtration rate, and hemoglobin A1c). Based on these PRSs, we developed multi‐trait PRS and considered as a primary exposure. Three nongenetic factors (smoking, alcohol drinking, and educational attainment) from the self‐reported questionnaire were also examined. Results During a median 12.1‐year follow‐up period, a total of 472 all‐cause and 79 cardiovascular disease mortality cases were documented. Compared with 0% to 90% of multi‐trait PRSs, an adjusted hazard ratio (HR) among the top 10% of multi‐trait PRSs was 1.32 (95% CI, 1.00–1.73) for all‐cause death and 2.63 (95% CI, 1.48–4.67) for cardiovascular disease death. Incorporation of educational attainment with multi‐trait PRSs showed null associations in those who went beyond high school (HR, 2.07 [95% CI, 0.44–9.66]) even in the top 10% of multi‐trait PRS. Conclusions Our analysis combining both genetic and nongenetic determinants highlighted that lifestyle factors and educational attainment can slightly reduce an individual's composite genetic risk for cardiovascular disease death.

Year:

2025

Background and Objective Health impacts of inhaling airborne microplastics have been actively investigated. Although microplastics have been detected in lung tissues and bronchoalveolar lavage fluids, their detection requires substantial effort and is technically challenging, with existing studies demonstrating various limitations. Bronchoalveolar lavage fluid is a less invasive sampling method than surgical lung biopsy. This study aimed to establish a detection method for microplastics from bronchoalveolar lavage fluid and evaluate the relevant health impacts. Methods Patients undergoing bronchoscopy for diffuse lung disease diagnosis were included. Microplastics were detected using Nile Red staining and fluorescence microscopy. Particle size, shape, and concentration were assessed through image analysis, and plastic types were identified via Raman spectroscopy. Correlations between microplastic findings and clinical laboratory data were evaluated. Results Microplastics were detected in the bronchoalveolar lavage fluid of all 30 patients. The median concentration of Nile Red‐stained particles was 684.7 particles/mL, and over 80.0% of the particles were smaller than 10 μm, with 93.5% being particulate and 6.5% fibre. The most frequently identified microplastics were polyvinyl chloride, polystyrene, and polyethylene terephthalate. Microplastic concentration positively correlated with blood C‐reactive protein levels (r s = 0.39) and was higher in areas showing consolidation shadows ( p = 0.024). Conclusions We established a method for detecting microplastics in bronchoalveolar lavage fluid. Microplastics were found in all patients, with a potential link to inflammation. In addition, Nile Red staining was applied for the first time to detect plastics in the lung and appeared to be useful for screening and quantification. image

Year:

2025

Background Current guidelines recommend placing an implantable cardiac defibrillator for patients with cardiac sarcoidosis and a severely impaired left ventricular ejection fraction (LVEF) of ≤35%. In this study, we determined the association between mild or moderate LVEF impairment and fatal ventricular arrhythmic event (FVAE). Methods and Results We retrospectively analyzed 401 patients with cardiac sarcoidosis without sustained ventricular arrhythmia at diagnosis. The primary end point was an FVAE, defined as the combined endpoint of documented ventricular tachycardia or ventricular fibrillation and sudden cardiac death. Two cutoff points for LVEF were used: a sex‐specific lower threshold of normal range of LVEF (52% for men and 54% for women) and an LVEF of 35%, which is used in the current guidelines. During a median follow‐up of 3.2 years, 58 FVAEs were observed, and the 5‐ and 10‐year estimated incidences of FVAEs were 16.8% and 23.0%, respectively. All patients were classified into 3 groups according to LVEF: impaired LVEF group, mild to moderate impairment of LVEF group, and maintained LVEF group. Multivariable competing risk analysis showed that both the impaired LVEF group (hazard ratio [HR], 3.24 [95% CI, 1.49–7.04]) and the mild to moderate impairment of LVEF group (HR, 2.16 [95% CI, 1.04–4.46]) were associated with a higher incidence of FVAEs than the maintained LVEF group after adjustment for covariates. Conclusions Patients with cardiac sarcoidosis are at a high risk of FVAEs, regardless of documented ventricular arrhythmia at the time of diagnosis. In patients with cardiac sarcoidosis, mild to moderate impairment of LVEF is associated with FVAEs.

Year:

2024

Year:

2024

Year:

2024

Background Post-authorization safety studies (PASSs) of vaccines are important. PASSs enable the evaluation of association between vaccination and adverse events following immunization through common study designs. Clinical trials during vaccine development typically include a few thousand to 10,000 participants while a PASS might aim to detect a few adverse events per 100,000 vaccine recipients. While all available data may be utilized, prior consideration of power analyses are nonetheless crucial for interpretation in cases where statistically significant differences are not found. Methods This research primarily examined cohort study design and self-controlled case series (SCCS) design, estimating the power of a PASS under plausible conditions. Results Both the cohort study and SCCS designs necessitated large sample sizes or high event counts to guarantee adequate power. The SCCS design is particularly suited to evaluating rare adverse events. However, extremely rare events may not yield sufficient occurrences, thereby resulting in low power. Although the SCCS design can more efficiently control for time-invariant confounding in principle, it solely estimates relative measures. A cohort study design might be preferred if confounding can be adequately managed as it also estimates absolute measures. It may be an easy decision to use all the data at hand for either design. We found it necessary to estimate the sample size and number of events to be used in the study based on a priori information and anticipated results.

Year:

2024

Background Previous studies have shown conflicting evidence regarding the incidence of cancer in patients with systemic lupus erythematosus (SLE) compared with that in healthy individuals. Calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus have been widely used to treat SLE; however, their effects on cancer risk remain unclear. We aimed to investigate the incidence of cancer in patients with SLE and determine the potential association between CNI use and cancer risk. Methods The standardized incidence ratio (SIR) of cancer among patients with lupus in the Lupus Registry of Nationwide Institutions (LUNA) was calculated based on the age-standardized incidence rate of cancer reported by Japan’s Ministry of Health, Labour and Welfare. We also examined the association between CNI exposure and cancer risk, while considering potential confounding factors. The analysis accounted for confounding variables such as age, sex, smoking history, maximum glucocorticoid dose, treatment history with cyclophosphamide, ongoing hydroxychloroquine, Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SDI) value (excluding cancer occurrence), comorbidity of diabetes mellitus, and smoking history. Results The study included 704 patients with SLE (625 females; 88.8%) with a median age of 44 years [interquartile range (IQR) = 34–55] years. The median past maximum glucocorticoid dose was 40 mg/day [IQR = 30–60 mg/day], and the SDI at registration was 1 [IQR = 0–2]. Among the patients, 246 (35.1%) had smoking histories, and 38 (5.4%) experienced cancer complications. Gynecological malignancies accounted for 63.2% of all cancers. The SIR of cancer in the LUNA cohort was 1.08 (95% confidence interval [CI] = 0.74–1.43). No statistically significant risks of cancer were found in relation to CNI treatment history; the odds ratio using multiple logistic regression was 1.12 (95% CI = 0.42–3.00), the risk ratio using standardization was 1.18 (95% CI = 0.47–2.16), and the risk ratio using inverse probability weighting was 1.8 (95% CI = 0.41–4.66). Conclusions The incidence of cancer in patients with SLE in the LUNA cohort did not significantly differ from that in the general population. These findings suggest that CNI treatment in this cohort did not pose a risk factor for cancer development.

Year:

2024

Year:

2024

Background Hypertension is a major modifiable risk factor for cardiovascular disease that affects approximately 43 million people in Japan. Although lifestyle modifications are recommended as first-line interventions, their implementation within clinical settings remains challenging. Following regulatory approval of a digital therapeutic (DTx) for hypertension in Japan in 2022, we evaluated its real-world effectiveness, particularly among demographics previously excluded from clinical trials. Methods Practice-based, real-world data from patients prescribed CureApp HT between September 2022 and December 2023 were analyzed. Participants who were ≥18 years old and had at least one baseline morning blood pressure recording were included and followed for 24 weeks. The primary outcome was a change in the morning home systolic blood pressure (SBP), whereas the secondary outcomes included other blood pressure parameters and app usage metrics such as individual app engagement proportion and in-app program durations. Statistical analyses included multivariable linear regression models to evaluate between-subgroup differences while adjusting for baseline characteristics including baseline SBP levels and seasonal timing of DTx initiation. Results Among the 2038 eligible patients, mean age was 55.8 ± 11.4 years and 48.8% were female. Morning home SBP decreased from baseline at week 12 (−4.8 mmHg; 95% confidence interval [CI], −5.3 to −4.4) and week 24 (−6.0 mmHg; 95% CI, −6.6 to −5.4), with corresponding reductions in other blood pressure parameters. Consistent benefits were observed across subgroups, including older adults (≥65 years; −6.6 mmHg at week 24) and those on antihypertensive medication (−5.2 mmHg) who had previously been excluded from clinical trials. Multivariable analyses identified baseline SBP and seasonal timing of DTx initiation as determinants of treatment response, with smaller reductions having been observed with summer initiation than with spring initiation. Furthermore, good app usage metrics, including high individual app engagement and reduced in-app program durations, promoted increased SBP reductions. Conclusions Real-world evidence demonstrates that a DTx designed for individuals with hypertension effectively reduced blood pressure across diverse patient populations, with baseline SBP, seasonal factors, and patient engagement significantly influencing treatment efficacy. These findings provide important clinical insights for optimizing daily digital hypertension management.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Yoshimasa Tanaka

Professor

Nagasaki University

JAPAN
View details

Kazuomi Kario

-

JAPAN
View details

Ryosuke Fujii

Senior Assistant Professor

Fujita Health University

JAPAN
View details

Shotaro Ide

Senior Assistant Professor

Nagasaki University Hospital

JAPAN
View details

Tatsuhiro Shibata

Kurume University

JAPAN
View details

Tomoyuki Tanigawa

St. Luke's International University

JAPAN
View details

Takao Ayuse

Nagasaki University Hospital

JAPAN
View details

Yudai Fujimoto

Juntendo University Hospital

JAPAN
View details

Koji Suzuki

Professor

Fujita Health University

JAPAN
View details

Hiroaki Ikezaki

Associate Professor

Kyushu University Graduate School of Medical Sciences

JAPAN
View details

Masayuki Takamura

-

JAPAN
View details

Mako Nagayoshi

Lecturer

Nagoya University Graduate School of Medicine

JAPAN
View details

Motohiro Sekino

Professor

Saga University

JAPAN
View details

Akihiro Nomura

Assistant Professor

Kanazawa University

JAPAN
View details

Takeru Nabeta

Assistant Professor

Kitasato University School of Medicine

JAPAN
View details

Shohei Kaneko

Nagasaki University Hospital

JAPAN
View details

Koichi Node

教授

Saga University

JAPAN
View details